Universal Chimeric Antigen Receptor-modified AT19 Cells for CD19+ Relapsed/Refractory Hematological Malignancies

• Status: Recruiting
• Trial end date: 2024-03-10

Summary

This is a single-center, open-label, single-arm study to evaluate the primary safety and efficacy of universal chimeric antigen receptor-modified AT19 cells in patients with relapsed or refractory hematological malignancies.

• Phase: Phase 1

Details

• Lead Sponsor: Wuhan Union Hospital, China
• Collaborator: Chengdu USino Technology Biology Co., Ltd
• Treatments: Cyclophosphamide; Fludarabine